drugset / Trial / NCT00820898

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT00820898 ↗

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying the side effects of gemcitabine and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2009-02
Primary completion
2011-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous